Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CD180 is a cell surface molecule consisting of extracellular leucine-rich repeats (LRR) and a short cytoplasmic tail. Additionally we are shipping CD180 Proteins (7) and CD180 Kits (2) and many more products for this protein.
Showing 10 out of 133 products:
Human Monoclonal CD180 Primary Antibody for Func, IHC (fro) - ABIN1105954
Miura, Shimazu, Miyake, Akashi, Ogata, Yamashita, Narisawa, Kimoto: RP105 is associated with MD-1 and transmits an activation signal in human B cells. in Blood 1998
Show all 2 references for ABIN1105954
Human Monoclonal CD180 Primary Antibody for FACS, IP - ABIN2663107
Miura, Miyake, Yamashita, Shimazu, Copeland, Gilbert, Jenkins, Inazawa, Abe, Kimoto: Molecular cloning of a human RP105 homologue and chromosomal localization of the mouse and human RP105 genes (Ly64 and LY64). in Genomics 1997
Show all 2 references for ABIN2663107
Mouse (Murine) Monoclonal CD180 Primary Antibody for FACS - ABIN1105959
Miyake, Shimazu, Kondo, Niki, Akashi, Ogata, Yamashita, Miura, Kimoto: Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression. in Journal of immunology (Baltimore, Md. : 1950) 1998
Show all 2 references for ABIN1105959
Mouse (Murine) Monoclonal CD180 Primary Antibody for FACS - ABIN1105957
Nagai, Shimazu, Ogata, Akashi, Sudo, Yamasaki, Hayashi, Iwakura, Kimoto, Miyake: Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide. in Blood 2002
Show all 2 references for ABIN1105957
Human Polyclonal CD180 Primary Antibody for EIA, IHC (p) - ABIN500626
Takeda, Kaisho, Akira: Toll-like receptors. in Annual review of immunology 2003
Human Monoclonal CD180 Primary Antibody for Func, FACS - ABIN614758
Divanovic, Trompette, Atabani, Madan, Golenbock, Visintin, Finberg, Tarakhovsky, Vogel, Belkaid, Kurt-Jones, Karp: Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. in Nature immunology 2005
The findings of association in different populations with different SNPs support a conclusion that variation close to the ANKRA2 (show ANKRA2 Antibodies)/CD180 locus analysed in this study contributes to differential response to pathogen exposure.
The role of TLR2 (show TLR2 Antibodies), TLR4 (show TLR4 Antibodies) and RP105/MD1 (show LY86 Antibodies) in the immunoregulatory effect of acidic exopolysaccharides from Lactobacillus plantarum N14 (show CLPTM1 Antibodies), is reported.
Data show that RP105 (show GPR83 Antibodies) knockout (-/-) smooth muscle cells and mast cells secreted higher levels of chemokine (C-C motif) ligand 2 (show CCL2 Antibodies) protein (CCL2 (show CCL2 Antibodies)).
These data unveil a novel innate immune signaling axis that orchestrates key cytokine responses of macrophages and provide molecular insight into the functions of RP105 (show GPR83 Antibodies) as an innate immune receptor for mycobacteria.
RP105 (show GPR83 Antibodies) regulates monocyte-driven arteriogenesis in a murine hind limb ischemia model.
RP105 deficiency results in reduced early atherosclerotic plaque development with a marked decrease in lesional macrophage content, which may be due to disturbed migration of RP105 deficient monocytes resulting from CCR2 downregulation
Deficiency of the endogenous TLR4 (show TLR4 Antibodies) inhibitor, RP105 (show GPR83 Antibodies), leads to pronounced cardiac dilation after myocardial infarction.
Data indicate that RP105 (show GPR83 Antibodies) and TLR4 (show TLR4 Antibodies) are both expressed by vascular smooth muscle cells (VSMC).
RP105 (show GPR83 Antibodies) deficiency on circulating cells results in an intriguing unexpected TLR-associated mechanisms that decrease atherosclerotic lesion formation with alterations on proinflammatory B2 B cells.
The function of TLR2 (show TLR2 Antibodies) and TLR4 (show TLR4 Antibodies) in response to TLR ligands could be associated with each other by RP105 (show GPR83 Antibodies).
Data show that both RP105 (show GPR83 Antibodies)/MD-1 (show LY86 Antibodies) and TLR4 (show TLR4 Antibodies)/MD-2 (show LY96 Antibodies) are expressed in marginal zone (MZ) B cells.
The RP105 (show GPR83 Antibodies)/MD-1 (show LY86 Antibodies) complex is a major mediator of adipose tissue inflammation independent of TLR4 (show TLR4 Antibodies) signaling and may represent a novel therapeutic target for obesity-associated metabolic disorders.
CD180 expression is significantly upregulated in human masticatory mucosa during wound healing
By associating with PIM (show PIM1 Antibodies)-1L, CD180 can thus obtain autonomous signaling capabilities, and this complex is then channeling inflammatory signals into B cell survival programs
Since MEC1 (show ATR Antibodies) cells are derived from a CLL patient with mutated IGVH genes (M-CLL) negative correlation between CD180 and CD32 (show FCGR2B Antibodies) expression on cycling MEC1 (show ATR Antibodies) cells could be limited to M-CLL.
we address of monocytes functional status through assessment of the patterns of expression of Fcgamma receptors CD64 (show FCGR1A Antibodies), CD32 (show FCGR2B Antibodies), CD16 (show CD16 Antibodies) and CD180 receptor on monocytes from CLL patients and healthy individuals using specific mAbs and flow cytometry.
Data indicate that TLR9 (show TLR9 Antibodies)-signaling as a crucial factor for turning retinoic acid (RA) into a strong stimulator of RP105-mediated B-cell proliferation.
IL-4 (show IL4 Antibodies) failed to up-regulate expression of RP105 at the cell surface. In conclusion, the anti-inflammatory actions of IL-4 (show IL4 Antibodies) occur independently of IL-10 (show IL10 Antibodies), RP105, and the kinase activity of RIPK2 (show RIPK2 Antibodies)
Both mouse and human RP105/MD-1 (show LY86 Antibodies) exhibit dimerization of the 1:1 RP105/MD-1 (show LY86 Antibodies) complex, demonstrating a novel organization.
Lower mRNA expression of LY64 was detected in gingival tissue of chronic periodontitis patients compared to healthy controls.
Data show that CD180, CD284 (show TLR4 Antibodies) and CD14 (show NDUFA2 Antibodies) expression is higher on normal B cells than on CD19 (show CD19 Antibodies)+ B-cell chronic lymphocytic leukaemia cells.
RP105 cross-linkaage enhanced B-lymphocyte (show AKAP17A Antibodies) proliferation, TLR9 (show TLR9 Antibodies) expression, and growth.
CD180 is a cell surface molecule consisting of extracellular leucine-rich repeats (LRR) and a short cytoplasmic tail. The extracellular LRR is associated with a molecule called MD-1 and form the cell surface receptor complex, RP105/MD-1. It belongs to the family of pathogen receptors, Toll-like receptors (TLR). RP105/MD1, by working in concert with TLR4, controls B cell recognition and signaling of lipopolysaccharide (LPS), a membrane constituent of Gram-negative bacteria.
, lymphocyte antigen 78
, CD180 molecule
, radio protective 105
, lymphocyte antigen 64-like protein
, radioprotective 105 kDa protein
, lymphocyte antigen 64
, lymphocyte antigen-64, radioprotective, 105kDa